SEC Form 8-K Summary
Registrant: Social Capital Hedosophia Holdings Corp. III (SCH), in connection with its proposed business combination with Clover Health Investments, Corp. The report was dated December 14, 2020, with an earliest event date of December 9, 2020.
Business Context and Reporting Period
This filing concerns the proposed business combination between SCH and Clover, the related shareholder vote, and the planned exchange listing of the post-combination company. It is not a periodic financial report and does not provide operating results for a reporting period.
Key Financial Metrics and Capitalization
- The filing does not provide clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, or other operating financial metrics.
- Completion of the transaction remains subject to, among other conditions, shareholder approval, minimum trust account funds after redemptions, regulatory approvals, and other customary closing conditions.
- The filing references a potential private investment in public equity (PIPE) transaction but does not provide transaction proceeds or other clear financial terms.
Material Changes and Transaction Update
- SCH determined, subject to closing of the Business Combination, to voluntarily withdraw its ordinary shares, warrants, and units from the New York Stock Exchange.
- The post-combination company is expected to list its Class A common stock and warrants on Nasdaq under the symbols CLOV and CLOW, respectively. The filing text identifies the warrant symbol as “CLOVW.”
- The last NYSE trading day was expected to be on or about January 7, 2021, with Nasdaq trading expected to begin at market open on or about January 8, 2021.
- Closing was expected on or about January 7, 2021, subject to final shareholder approval at the extraordinary general meeting scheduled for January 6, 2021, and satisfaction of other conditions.
- SCH issued a press release regarding the planned listing and shareholder meeting; the press release was furnished as Exhibit 99.1.
Outlook, Risks, and Contingencies
The expected closing and Nasdaq listing are forward-looking statements and are not guaranteed. Key risks include failure or delay in completing the transaction, failure to obtain shareholder or regulatory approvals, insufficient trust account funds following redemptions, inability to complete the PIPE investment, termination of the merger agreement, legal proceedings, business disruption and employee-retention difficulties, exchange-listing risks, market volatility, changes in healthcare regulation, and the ability of the combined company to execute its business plans.
The filing directs investors to the registration statement, definitive proxy statement/prospectus, and related SEC filings for additional transaction terms and risk factors. The Item 7.01 information and Exhibit 99.1 were furnished and were not deemed filed for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify whether shareholders approved the Business Combination and whether all closing conditions were satisfied.
- Confirm the actual closing date, redemption levels, minimum trust account balance, and any PIPE financing completed.
- Confirm the effective delisting from the NYSE and commencement of trading on Nasdaq under the stated symbols.
- Review the definitive proxy statement/prospectus and registration statement for transaction economics, dilution, capitalization, and detailed risk factors.
- Verify the final legal entity, share classes, warrant terms, and post-combination ownership structure.